세계의 카테터 시장 : 유형별, 적응증별, 최종 사용자별, 지역별 예측(-2030년)

The catheters market is projected to grow steadily, driven by the increasing adoption of image-guided and minimally invasive catheter-based procedures across cardiovascular, urological, and neurological applications. Innovations such as steerable and pressure-sensitive catheters, drug-coated technologies, and antimicrobial coatings improve procedural outcomes and reduce complication rates.

Additionally, the rising deployment of AI-powered navigation and real-time imaging in interventional cardiology and neurology enhances procedural precision, particularly in complex cases. Demand is further fueled by the development of hybrid operating rooms and catheter labs in tertiary care settings, enabling advanced interventions. These specialized advancements propel the market's consistent growth trajectory, especially in regions facing high procedural volumes and increasing lifestyle-related diseases.

"By type, the cardiovascular catheters segment accounted for the largest market in 2024."

The cardiovascular catheters segment accounted for the largest market in 2024, and this trend is projected to continue during the forecast period. The growth of this segment is fueled by the increasing incidence of heart conditions, such as coronary artery disease, heart failure, and arrhythmias, particularly among older adults, often requiring minimally invasive procedures like angioplasty and ablation, which involve the use of catheters. Advancements in catheter technologies, including drug-eluting and imaging-compatible catheters, have improved procedure safety and outcomes. Additionally, the rising awareness of people regarding early cardiac care and favorable reimbursement policies is driving continuous R&D investments by key players, further boosting the segment's growth.

"By end user, the hospitals segment accounted for the largest share in the catheters market in 2024."

The hospitals segment accounted for the largest share of the global catheters market in 2024. The segment's position can be attributed to the high volume of procedures performed in these settings and the availability of advanced medical infrastructure. Hospitals handle various catheter-based treatments, including cardiovascular, urinary, and neurological procedures requiring skilled professionals and specialized equipment. The rising number of inpatient admissions for chronic conditions, such as heart disease and kidney disorders, is also contributing to this demand. Hospitals are better equipped to adopt advanced catheter technologies and ensure proper infection control practices. Additionally, many countries' strong reimbursement support for hospital-based procedures further boosts utilization. All these factors collectively make hospitals the largest end users of catheters.

"North America accounted for the largest share of the global catheters market in 2024."

North America accounted for the largest market in the global catheters market, mainly due to its advanced healthcare infrastructure, high healthcare spending, and early adoption of innovative medical technologies. Additionally, the region sees a high prevalence of chronic diseases like cardiovascular disorders, kidney failure, and urinary incontinence, which significantly drives the demand for various catheter types. Moreover, leading catheter manufacturers, strong distribution networks, and well-established reimbursement policies support widespread usage across hospitals, clinics, and ambulatory surgical centers. Favorable regulatory approvals, growing preference for minimally invasive procedures, and rising geriatric population further boost the market. These combined factors make North America the dominant global catheter market in the region.

Breakdown of Supply-side Primary Interviews:

• By Company Type: Tier 1 - 45%, Tier 2 - 20%, and Tier 3 - 35%
• By Designation: C-level Executives - 35%, Directors - 25%, and Other Designations - 40%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, Middle East & Africa - 5%

Research Coverage

This report studies the catheters market in terms of type, indication, end user, and region. It also studies market growth factors (drivers, restraints, opportunities, and challenges). The report further analyzes the market's opportunities and challenges and details the competitive landscape for market leaders. It analyzes micro markets concerning their growth trends and forecasts the revenue of the market segments concerning five main regions and respective countries.

Reasons to Buy the Report

The report can help established and new entrants/smaller firms gauge the market's pulse, which, in turn, would help them garner a greater share. The report provides insights into the following pointers:

• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the catheters market
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the catheters market
• Market Development: Comprehensive information about lucrative emerging markets across regions
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the catheters market
• Competitive Assessment: In-depth assessment of market share, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the catheters market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 MARKETS COVERED
  • 1.2.2 INCLUSIONS & EXCLUSIONS
  • 1.2.3 YEARS CONSIDERED
• 1.3 CURRENCY
• 1.4 UNIT CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CATHETERS MARKET OVERVIEW
• 4.2 NORTH AMERICA: CATHETERS MARKET OVERVIEW
• 4.3 CATHETERS MARKET: REGIONAL MIX
• 4.4 CATHETERS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
• 4.5 CATHETERS MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising geriatric population
    • 5.2.1.2 Increasing prevalence of chronic diseases
    • 5.2.1.3 Increased awareness and treatment of urinary incontinence
    • 5.2.1.4 Rising demand for minimally invasive surgeries
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Product recalls and failures
    • 5.2.2.2 Presence of substitute medical devices
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand in emerging markets
    • 5.2.3.2 Technological advancements and product innovation
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Integration complexity with existing production lines
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Antimicrobial-coated catheters
    • 5.3.1.2 Drug-eluting catheters
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Hydrophilic coatings for catheters
    • 5.3.2.2 Ultrasound-guided insertion systems
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Minimally invasive surgical devices
• 5.4 PORTER'S FIVE FORCES ANALYSIS
  • 5.4.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4.2 BARGAINING POWER OF BUYERS
  • 5.4.3 BARGAINING POWER OF SUPPLIERS
  • 5.4.4 THREAT OF SUBSTITUTES
  • 5.4.5 THREAT OF NEW ENTRANTS
• 5.5 REGULATORY LANDSCAPE
  • 5.5.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.5.2 REGULATORY FRAMEWORK
    • 5.5.2.1 North America
      • 5.5.2.1.1 US
      • 5.5.2.1.2 Canada
    • 5.5.2.2 Europe
    • 5.5.2.3 Asia Pacific
      • 5.5.2.3.1 China
      • 5.5.2.3.2 Japan
      • 5.5.2.3.3 India
    • 5.5.2.4 Latin America
      • 5.5.2.4.1 Brazil
      • 5.5.2.4.2 Mexico
    • 5.5.2.5 Middle East
    • 5.5.2.6 Africa
• 5.6 PATENT ANALYSIS
  • 5.6.1 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR CATHETERS MARKET, JANUARY 2015-DECEMBER 2025
  • 5.6.2 LIST OF MAJOR PATENTS, 2023-2024
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR HS CODE 901839, 2020-2024
  • 5.7.2 EXPORT DATA FOR HS CODE 901839, 2020-2024
• 5.8 REIMBURSEMENT SCENARIO
• 5.9 KEY CONFERENCES & EVENTS, 2025-2026
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE, 2022-2024
  • 5.11.2 AVERAGE SELLING PRICE TREND OF CATHETERS, BY REGION, 2022-2024
• 5.12 VALUE CHAIN ANALYSIS
• 5.13 ECOSYSTEM ANALYSIS
• 5.14 IMPACT OF AI/GEN AI ON CATHETERS MARKET
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 CATHETERS MARKET: IMPACT OF 2025 US TARIFF
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 IMPACT ON COUNTRY/REGION
    • 5.17.4.1 North America
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
  • 5.17.5 IMPACT ON END USERS
    • 5.17.5.1 Hospitals
    • 5.17.5.2 Ambulatory surgical centers
    • 5.17.5.3 Long-term care facilities
    • 5.17.5.4 Diagnostic imaging centers
    • 5.17.5.5 Outpatient clinics
    • 5.17.5.6 Other end users

6 CATHETERS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 CARDIOVASCULAR CATHETERS
  • 6.2.1 HIGH PREVALENCE OF CARDIOVASCULAR DISEASES AND GROWING INTERVENTIONAL PROCEDURES TO FUEL DEMAND
  • 6.2.2 ELECTROPHYSIOLOGY CATHETERS
    • 6.2.2.1 Increasing prevalence of atrial fibrillation and expansion of electrophysiology labs to drive segment
  • 6.2.3 ANGIOGRAPHY CATHETERS
    • 6.2.3.1 Growing use of minimally invasive diagnostics and better imaging outcomes to propel growth
  • 6.2.4 CORONARY BALLOON CATHETERS
    • 6.2.4.1 Rapid growth in percutaneous coronary interventions and technological innovation to support growth
  • 6.2.5 IVUS/OCT CATHETERS
    • 6.2.5.1 Integration of intravascular imaging into PCI and clinical guidelines to drive uptake
  • 6.2.6 GUIDING CATHETERS
    • 6.2.6.1 Versatility in access and support during complex interventions to boost demand
  • 6.2.7 OTHER CARDIOVASCULAR CATHETERS
• 6.3 INTRAVENOUS CATHETERS
  • 6.3.1 INCREASING USE IN LONG-TERM THERAPIES AND HOSPITAL-ACQUIRED INFECTION PREVENTION EFFORTS TO DRIVE GROWTH
  • 6.3.2 GLOBAL VOLUME ANALYSIS OF INTRAVENOUS CATHETER TYPES, 2023-2030 (THOUSAND UNITS)
  • 6.3.3 CENTRAL VENOUS CATHETERS
    • 6.3.3.1 Rising use in intensive and emergency care, along with multi-lumen design advancements, to drive demand
    • 6.3.3.2 Peripherally inserted central catheters
      • 6.3.3.2.1 Preference for long-term, outpatient IV therapy and reduced complication rates to drive use
    • 6.3.3.3 Non-tunneled central venous catheters
      • 6.3.3.3.1 Immediate access in emergency and ICU settings supports continued use
    • 6.3.3.4 Skin-tunneled central venous catheters
      • 6.3.3.4.1 Low infection risk and suitability for long-term therapies drive adoption
    • 6.3.3.5 Implantable ports
      • 6.3.3.5.1 Rise in cancer prevalence and demand for discreet, low-maintenance access devices drive use
  • 6.3.4 PERIPHERAL INTRAVENOUS CATHETERS
    • 6.3.4.1 High frequency of use and cost-effectiveness drive widespread adoption
  • 6.3.5 MIDLINE PERIPHERAL CATHETERS
    • 6.3.5.1 Rising preference in infection-prone patients and long-duration therapies to fuel market growth
• 6.4 UROLOGICAL CATHETERS
  • 6.4.1 AGING POPULATION AND RISE IN RENAL AND UROLOGICAL DISORDERS TO DRIVE DEMAND
  • 6.4.2 URINARY CATHETERS
    • 6.4.2.1 Rising geriatric population and increased incidence of urinary incontinence - key drivers of growth
    • 6.4.2.2 Indwelling catheters
      • 6.4.2.2.1 Hospital-acquired urinary retention cases and long-term catheterization needs to drive demand
    • 6.4.2.3 Intermittent catheters
      • 6.4.2.3.1 Rising preference for self-catheterization and reduced infection risk accelerates adoption
    • 6.4.2.4 External catheters
      • 6.4.2.4.1 Growing use of non-invasive options in female and bedridden patients to fuel demand
  • 6.4.3 DIALYSIS CATHETERS
    • 6.4.3.1 Rising prevalence of end-stage renal disease and need for immediate vascular access to drive use
    • 6.4.3.2 Peritoneal dialysis catheters
      • 6.4.3.2.1 Preference for home-based renal therapy to support segment growth
    • 6.4.3.3 Hemodialysis catheters
      • 6.4.3.3.1 Increasing prevalence of end-stage renal disease and urgency for rapid vascular access to drive demand
• 6.5 SPECIALTY CATHETERS
  • 6.5.1 DIVERSE CLINICAL UTILITY AND ADVANCEMENTS IN MINIMALLY INVASIVE MONITORING TO SUPPORT GROWTH
  • 6.5.2 PRESSURE & HEMODYNAMIC CATHETERS
    • 6.5.2.1 Precision in critical care and expanding cardiac monitoring - key drivers
  • 6.5.3 TEMPERATURE MONITORING CATHETERS
    • 6.5.3.1 Segment to gain traction due to need for precise core temperature control in critical illness
  • 6.5.4 INTRAUTERINE INSEMINATION CATHETERS
    • 6.5.4.1 Rising use of assisted reproduction and favorable clinical outcomes support growth of segment
  • 6.5.5 OTHER SPECIALTY CATHETERS
• 6.6 NEUROVASCULAR CATHETERS
  • 6.6.1 INCREASING STROKE BURDEN AND SHIFT TOWARD ENDOVASCULAR THERAPY TO ACCELERATE DEMAND

7 CATHETERS MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 CARDIAC DISEASES
  • 7.2.1 GROWING CARDIOVASCULAR DISEASE BURDEN TO DRIVE DOMINANCE OF SEGMENT
• 7.3 NEUROVASCULAR CONDITIONS
  • 7.3.1 INCREASING STROKE INCIDENCE AND ADVANCED NEURO-INTERVENTION TECHNIQUES TO FUEL SEGMENT
• 7.4 URINARY CONDITIONS
  • 7.4.1 RISING CASES OF URINARY INCONTINENCE AND UROLOGICAL DISORDERS TO DRIVE DEMAND
• 7.5 VASCULAR DISEASES
  • 7.5.1 PREVALENCE OF PERIPHERAL ARTERY DISEASE AND DEEP VEIN THROMBOSIS AIDS GROWTH OF SEGMENT
• 7.6 IV MEDICATION DELIVERY & FLUID MANAGEMENT
  • 7.6.1 GROWING USE OF LONG-TERM IV THERAPY IN CHRONIC CONDITIONS TO SUPPORT EXPANSION OF SEGMENT
• 7.7 KIDNEY DISEASES
  • 7.7.1 HIGH GLOBAL BURDEN OF END-STAGE RENAL DISEASE TO ACCELERATE GROWTH
• 7.8 BLOOD TRANSFUSION
  • 7.8.1 INCREASE IN SURGICAL VOLUME AND CRITICAL CARE NEEDS TO DRIVE DEMAND
• 7.9 OTHER INDICATIONS

8 CATHETERS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 RAPID EXPANSION OF HOSPITAL CAPACITY AND INFRASTRUCTURE TO DRIVE MARKET
• 8.3 AMBULATORY SURGICAL CENTERS
  • 8.3.1 SURGE IN OUTPATIENT PROCEDURES AND REGULATORY SUPPORT TO SPUR GROWTH
• 8.4 LONG-TERM CARE FACILITIES
  • 8.4.1 AGING POPULATION AND ASSISTED LIVING DEMAND INCREASED CATHETER USE
• 8.5 DIAGNOSTIC IMAGING CENTERS
  • 8.5.1 HIGH VOLUME OF IMAGING PROCEDURES BOOSTS CATHETER DEMAND
• 8.6 OUTPATIENT CLINICS
  • 8.6.1 RISING OUTPATIENT VISIT VOLUMES AND PROCEDURAL SHIFT INCREASE CATHETER USE
• 8.7 OTHER END USERS

9 CATHETERS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 NORTH AMERICA: VOLUME ANALYSIS OF INTRAVENOUS CATHETER TYPES, 2023--2030 (THOUSAND UNITS)
  • 9.2.3 US
    • 9.2.3.1 Rising chronic disease burden spurs innovation demand in catheter use
  • 9.2.4 CANADA
    • 9.2.4.1 Aging population and rising hypertension & urinary conditions lift catheter demand
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 EUROPE: VOLUME ANALYSIS OF INTRAVENOUS CATHETER TYPES, 2023-2030 (THOUSAND UNITS)
  • 9.3.3 GERMANY
    • 9.3.3.1 Aging population and high PCI volume to drive catheter usage
  • 9.3.4 UK
    • 9.3.4.1 High prevalence of long-term urinary catheter use maintained by community nursing demand
  • 9.3.5 FRANCE
    • 9.3.5.1 Widespread use of intermittent urinary catheters to support second-largest share
  • 9.3.6 SPAIN
    • 9.3.6.1 Rising UTI burden in nursing homes boosts urinary catheter demand
  • 9.3.7 ITALY
    • 9.3.7.1 Recent heightened CAUTI risk in ICUs underpins demand for safer urinary catheters
  • 9.3.8 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 ASIA PACIFIC VOLUME ANALYSIS OF INTRAVENOUS CATHETER TYPES, 2023-2030 (THOUSAND UNITS)
  • 9.4.3 JAPAN
    • 9.4.3.1 Aging population and rising cardiovascular care needs to boost demand for catheters
  • 9.4.4 CHINA
    • 9.4.4.1 High cardiovascular disease burden and expanding care access to drive demand
  • 9.4.5 INDIA
    • 9.4.5.1 Set to be fastest-growing market with escalating CVD incidence
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 High cardiovascular disease burden and strong government support to drive growth
  • 9.4.7 SOUTH KOREA
    • 9.4.7.1 Rising arrhythmia treatments and expanding interventional cardiology infrastructure bolster catheter demand
  • 9.4.8 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 LATIN AMERICA: VOLUME ANALYSIS OF INTRAVENOUS CATHETER TYPES, 2023-2030 (THOUSAND UNITS)
  • 9.5.3 BRAZIL
    • 9.5.3.1 Robust public healthcare infrastructure and high cardiovascular procedure volume drive dominance
  • 9.5.4 MEXICO
    • 9.5.4.1 High diabetes and cardiovascular disease prevalence spurs catheter demand
  • 9.5.5 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF INTRAVENOUS CATHETER TYPES, 2023-2030 (THOUSAND UNITS)
  • 9.6.3 GCC COUNTRIES
    • 9.6.3.1 Market uplift through strategic healthcare investments and rising procedure volumes
    • 9.6.3.2 Kingdom of Saudi Arabia (KSA)
      • 9.6.3.2.1 Market gains strength from healthcare transformation and NCD burden
    • 9.6.3.3 United Arab Emirates (UAE)
      • 9.6.3.3.1 Market growth anchored in advanced hospital infrastructure and medical tourism
    • 9.6.3.4 Other GCC Countries
  • 9.6.4 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 10.3 REVENUE ANALYSIS OF KEY PLAYERS IN CATHETERS MARKET (2022-2024)
• 10.4 MARKET SHARE ANALYSIS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Type footprint
    • 10.5.5.4 Indication footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 DYNAMIC COMPANIES
  • 10.6.3 STARTING BLOCKS
  • 10.6.4 RESPONSIVE COMPANIES
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of key emerging players/startups
• 10.7 BRAND/PRODUCT COMPARISON
• 10.8 R&D EXPENDITURE OF KEY PLAYERS
• 10.9 COMPANY VALUATION & FINANCIAL METRICS
  • 10.9.1 COMPANY VALUATION
  • 10.9.2 FINANCIAL METRICS
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT APPROVALS/LAUNCHES
  • 10.10.2 DEALS
  • 10.10.3 EXPANSIONS
  • 10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 BOSTON SCIENTIFIC CORPORATION
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches & approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 MEDTRONIC PLC
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 B. BRAUN SE
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
      • 11.1.3.3.2 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 BECTON, DICKINSON AND COMPANY
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches & approvals
      • 11.1.4.3.2 Deals
      • 11.1.4.3.3 Expansions
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses and competitive threats
  • 11.1.5 STRYKER CORPORATION
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches & approvals
      • 11.1.5.3.2 Deals
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses and competitive threats
  • 11.1.6 ABBOTT LABORATORIES
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches & approvals
      • 11.1.6.3.2 Deals
      • 11.1.6.3.3 Other developments
  • 11.1.7 TERUMO CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches & approvals
      • 11.1.7.3.2 Deals
      • 11.1.7.3.3 Expansions
  • 11.1.8 COLOPLAST A/S
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches & approvals
      • 11.1.8.3.2 Expansions
  • 11.1.9 CONVATEC GROUP PLC
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches & approvals
  • 11.1.10 MERIT MEDICAL SYSTEMS, INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Product launches & approvals
      • 11.1.10.3.2 Deals
  • 11.1.11 JOHNSON & JOHNSON
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches & approvals
      • 11.1.11.3.2 Deals
  • 11.1.12 COOK
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product launches & approvals
      • 11.1.12.3.2 Deals
  • 11.1.13 EDWARDS LIFESCIENCES CORPORATION
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
  • 11.1.14 NIPRO CORPORATION
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Expansions
  • 11.1.15 TELEFLEX INCORPORATED
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Product launches & approvals
      • 11.1.15.3.2 Deals
  • 11.1.16 CARDINAL HEALTH, INC.
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Expansions
  • 11.1.17 HOLLISTER INCORPORATED
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products offered
    • 11.1.17.3 Recent developments
      • 11.1.17.3.1 Expansions
  • 11.1.18 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    • 11.1.18.1 Business overview
    • 11.1.18.2 Products offered
  • 11.1.19 KONINKLIJKE PHILIPS N.V.
    • 11.1.19.1 Business overview
    • 11.1.19.2 Products offered
    • 11.1.19.3 Recent developments
      • 11.1.19.3.1 Expansions
  • 11.1.20 MICROPORT SCIENTIFIC CORPORATION
    • 11.1.20.1 Business overview
    • 11.1.20.2 Products offered
    • 11.1.20.3 Recent developments
      • 11.1.20.3.1 Product launches & approvals
• 11.2 OTHER PLAYERS
  • 11.2.1 AMECATH
  • 11.2.2 SIS MEDICAL AG
  • 11.2.3 ANGIPLAST PRIVATE LIMITED
  • 11.2.4 RELISYS MEDICAL DEVICES LIMITED
  • 11.2.5 CAGENT VASCULAR
  • 11.2.6 BIOTRONIK
  • 11.2.7 ADVIN HEALTH CARE
  • 11.2.8 ALVIMEDICA
  • 11.2.9 INGENION MEDICAL LIMITED
  • 11.2.10 SUMMA THERAPEUTICS, LLC

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
  • 12.3.1 PRODUCT ANALYSIS
  • 12.3.2 GEOGRAPHIC ANALYSIS
  • 12.3.3 COMPANY INFORMATION
  • 12.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
  • 12.3.5 COUNTRY-LEVEL VOLUME ANALYSIS
  • 12.3.6 PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
  • 12.3.7 ANY CONSULTS/CUSTOM STUDIES AS PER CLIENT REQUIREMENTS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS